Treatment of myasthenia gravis: focus on pyridostigmine. (Q37911501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Treatment of myasthenia gravis: focus on pyridostigmine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Lorenzo Maggi

1 reference

25 August 2017

publication date

1 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

691-701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis in the elderly: Is it different?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis: a higher than expected incidence in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Evidence of underdiagnosis of myasthenia gravis in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Lifetime course of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Are MuSK antibodies the primary cause of myasthenic symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Thymoma in patients with MG: characteristics and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Ocular myasthenia: diagnostic and treatment recommendations and the evidence base

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Guidelines for the treatment of autoimmune neuromuscular transmission disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Therapy of myasthenic crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Clinical pharmacokinetics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Juvenile myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Response to therapy in myasthenia gravis with anti-MuSK antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

The natural course of myasthenia gravis: a long term follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Latency and exposure-health associations in Gulf War veterans with early fatigue onsets: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

An Update on Myasthenic Crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenic crisis: guidelines for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis: management issues during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Antisense treatment for myasthenia gravis: experience with monarsen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis (MG): epidemiological data and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Successful treatment of refractory generalized myasthenia gravis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Rituximab for myasthenia gravis: three case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Etanercept treatment in corticosteroid-dependent myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Myasthenia gravis associated with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593300-000000000-00000

Mestinon in the treatment of myasthenia gravis

21 January 2018

1 reference

12 December 2020

Corticosteroids for myasthenia gravis

1 reference

12 December 2020

The Epidemiology of Myasthenia Gravis

1 reference

12 December 2020

Immunosuppressive agents for myasthenia gravis

1 reference

12 December 2020

Myasthenia gravis: prolonged treatment with steroids

1 reference

12 December 2020

Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience

1 reference

12 December 2020

1 reference

12 December 2020

Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide

1 reference

12 December 2020

The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis

1 reference

12 December 2020

Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis

1 reference

12 December 2020

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

1 reference

12 December 2020

Intravenous immunoglobulin for myasthenia gravis

1 reference

12 December 2020

Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure

1 reference

12 December 2020

Plasma exchange for myasthenia gravis.

1 reference

12 December 2020

The treatment of severe myasthenia gravis with immunosuppressive agents

1 reference

12 December 2020

Pyridostigmin (mestinon) in the treatment of myasthenia gravis

1 reference

12 December 2020

Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis

1 reference

12 December 2020

Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis

1 reference

12 December 2020

Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation

1 reference

12 December 2020

1 reference

12 December 2020

Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients

1 reference

12 December 2020

[Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring]

1 reference

12 December 2020

Duration of action of neostigmine and pyridostigmine in the elderly

1 reference

12 December 2020

Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care

1 reference

12 December 2020

Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis

1 reference

12 December 2020

Mestinon in myasthenia gravis; preliminary report

1 reference

12 December 2020

10.2165/11593300-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21815707%20AND%20SRC:MED&resulttype=core&format=json